MA42701B1 - Compositions d'insuline à action rapide - Google Patents

Compositions d'insuline à action rapide

Info

Publication number
MA42701B1
MA42701B1 MA42701A MA42701A MA42701B1 MA 42701 B1 MA42701 B1 MA 42701B1 MA 42701 A MA42701 A MA 42701A MA 42701 A MA42701 A MA 42701A MA 42701 B1 MA42701 B1 MA 42701B1
Authority
MA
Morocco
Prior art keywords
acting insulin
rapid acting
insulin compositions
insulin
analogue
Prior art date
Application number
MA42701A
Other languages
English (en)
Other versions
MA42701A (fr
Inventor
Michael Patrick Akers
Ranajoy Majumdar
Chi A Nguyen
Chad D Paavola
Virender Kumar Sarin
Nanette Elizabeth Schulte
Michael Edward Christe
Thomas Andrew Hardy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57003563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42701A publication Critical patent/MA42701A/fr
Publication of MA42701B1 publication Critical patent/MA42701B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

L'invention concerne une composition pharmaceutique d'insuline humaine ou d'analogue d'insuline, qui comprend du citrate, du tréprostinil et des agents de stabilisation, qui a une action pharmacocinétique et/ou pharmacodynamique plus rapide que des formulations commerciales de produits analogues d'insuline existants, et qui est stable pour une utilisation commerciale.
MA42701A 2015-08-27 2016-08-19 Compositions d'insuline à action rapide MA42701B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210469P 2015-08-27 2015-08-27
PCT/US2016/047723 WO2017034956A1 (fr) 2015-08-27 2016-08-19 Compositions d'insuline à action rapide

Publications (2)

Publication Number Publication Date
MA42701A MA42701A (fr) 2018-07-04
MA42701B1 true MA42701B1 (fr) 2023-01-31

Family

ID=57003563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42701A MA42701B1 (fr) 2015-08-27 2016-08-19 Compositions d'insuline à action rapide

Country Status (39)

Country Link
US (3) US9901623B2 (fr)
EP (2) EP3340966B1 (fr)
JP (2) JP6359780B2 (fr)
KR (1) KR102018998B1 (fr)
CN (1) CN107920992B (fr)
AR (1) AR105712A1 (fr)
AU (1) AU2016310475B2 (fr)
BR (1) BR112018001755A2 (fr)
CA (1) CA2994427C (fr)
CL (1) CL2018000503A1 (fr)
CO (1) CO2018002026A2 (fr)
CR (1) CR20180118A (fr)
DK (1) DK3340966T3 (fr)
DO (1) DOP2018000059A (fr)
EA (1) EA033396B1 (fr)
EC (1) ECSP18014922A (fr)
ES (1) ES2928664T3 (fr)
FI (1) FI3340966T3 (fr)
HR (1) HRP20221367T1 (fr)
HU (1) HUE060626T2 (fr)
IL (1) IL256939B (fr)
JO (1) JO3749B1 (fr)
LT (1) LT3340966T (fr)
MA (1) MA42701B1 (fr)
MD (1) MD3340966T2 (fr)
MX (1) MX2018002482A (fr)
MY (1) MY195781A (fr)
NZ (1) NZ739338A (fr)
PE (1) PE20180782A1 (fr)
PH (1) PH12018500422B1 (fr)
PL (1) PL3340966T3 (fr)
PT (1) PT3340966T (fr)
RS (1) RS63731B1 (fr)
SV (1) SV2018005643A (fr)
TN (1) TN2018000056A1 (fr)
TW (1) TWI614025B (fr)
UA (1) UA120142C2 (fr)
WO (1) WO2017034956A1 (fr)
ZA (1) ZA201800511B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034393B1 (ru) 2012-11-13 2020-02-03 Адосиа Состав инсулина быстрого действия, содержащий замещенное анионное соединение
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EA201992351A1 (ru) * 2017-06-01 2020-03-26 Эли Лилли Энд Компани Быстродействующие композиции инсулина
US11510967B2 (en) 2017-09-08 2022-11-29 Eli Lilly And Company Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol
US20210038506A1 (en) * 2018-04-04 2021-02-11 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
WO2019193349A1 (fr) * 2018-04-04 2019-10-10 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
US20210113763A1 (en) * 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
EA202190552A1 (ru) * 2018-09-18 2021-06-18 Эли Лилли Энд Компани Эрбуминовая соль трепростинила
EP3996679B1 (fr) * 2019-07-12 2023-09-06 Novo Nordisk A/S Formulation d'insuline à concentration élevée
CN115697379A (zh) * 2020-06-30 2023-02-03 江苏恒瑞医药股份有限公司 速效胰岛素组合物及其医药用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
EP0018609B1 (fr) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Solutions aqueuses de protéines, stables à la dénaturation, procédé pour leur fabrication et leur utilisation
ZA821243B (en) * 1981-03-10 1983-01-26 Novo Industri As Stabilized insulin preparation and method for their production
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK503386D0 (da) * 1986-10-20 1986-10-20 Novo Industri As Peptidpraeparater
AU612141B2 (en) 1987-02-25 1991-07-04 Novo Nordisk A/S Novel insulin derivatives
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
ATE220917T1 (de) 1999-01-26 2002-08-15 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
RU2300367C2 (ru) 1999-11-15 2007-06-10 Ханамарадди Т. ГАНГАЛ Жидкий лечебный состав для внутривенного введения, содержащий декстрозу и инсулин
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ES2360182T3 (es) 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
CN1917866B (zh) * 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
PT2319500E (pt) 2004-03-12 2013-01-23 Biodel Inc Composições de distribuição de fármacos de actuação rápida
EP1744739B1 (fr) * 2004-04-12 2010-03-31 United Therapeutics Corporation Utilisation de treprostinile pour traiter des ulceres diabetiques neuropathiques du pied
EP2292653B1 (fr) * 2005-02-02 2014-05-21 Novo Nordisk A/S Nouveaux dérivés d'insuline
WO2006082204A1 (fr) * 2005-02-02 2006-08-10 Novo Nordisk A/S Derives d'insuline
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
AU2006294565A1 (en) * 2005-09-30 2007-04-05 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
DE102006047613A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Peristaltische Mikropumpe mit wechselbarem Pumpenkopf
DE102006047538A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Medikamentendosiersystem mittels Mikropumpe
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
WO2009026517A2 (fr) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Thérapie pour complications du diabète
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2328636B1 (fr) 2008-08-28 2013-06-12 Medingo Ltd. Dispositif permettant l'absorption sous-cutanée accrue d'insuline
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
RU2533217C3 (ru) 2009-06-26 2020-12-21 Ново Нордиск А/С Препарат, содержащий инсулин, никотинамид и аминокислоту
ES2525748T3 (es) 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes
CA2805031A1 (fr) 2010-07-07 2012-01-12 Biodel, Inc. Compositions et procedes pour la modulation de la pharmacocinetique et de la pharmacodynamie de l'insuline
JP2014501239A (ja) 2010-12-14 2014-01-20 ノヴォ ノルディスク アー／エス インスリン、ニコチンアミドおよびアミノ酸を含む製剤
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
AU2012271361B2 (en) 2011-06-17 2017-03-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP5912426B2 (ja) * 2011-11-07 2016-04-27 ヤマハ発動機株式会社 リニアコンベア
MX361727B (es) 2011-12-30 2018-12-14 Halozyme Inc Variantes de polipeptido ph20, formulaciones y usos de las mismas.
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
US20150065423A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
KR102351111B1 (ko) 2014-01-13 2022-01-14 써멀린 다이어비티즈, 엘엘씨 초속효성 인슐린 제형 및 약제학적 전달 시스템
WO2015120457A1 (fr) * 2014-02-10 2015-08-13 Biodel Inc. Formulations d'insuline à action ultrarapide stabilisées
JO3624B1 (ar) * 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
US20180221385A1 (en) 2015-07-28 2018-08-09 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
UA120142C2 (uk) 2019-10-10
DOP2018000059A (es) 2018-04-15
TWI614025B (zh) 2018-02-11
EA033396B1 (ru) 2019-10-31
PL3340966T3 (pl) 2023-01-30
MY195781A (en) 2023-02-13
AU2016310475B2 (en) 2018-10-18
PH12018500422A1 (en) 2018-08-29
EA201890343A1 (ru) 2018-07-31
US10925931B2 (en) 2021-02-23
TW201717997A (zh) 2017-06-01
JP6935364B2 (ja) 2021-09-15
KR102018998B1 (ko) 2019-09-05
JO3749B1 (ar) 2021-01-31
JP2018507869A (ja) 2018-03-22
CN107920992B (zh) 2021-06-18
BR112018001755A2 (pt) 2018-09-18
DK3340966T3 (da) 2022-10-24
CL2018000503A1 (es) 2018-08-03
WO2017034956A1 (fr) 2017-03-02
JP2018172404A (ja) 2018-11-08
MA42701A (fr) 2018-07-04
PT3340966T (pt) 2022-12-05
KR20180033276A (ko) 2018-04-02
FI3340966T3 (fi) 2023-01-13
PE20180782A1 (es) 2018-05-07
ECSP18014922A (es) 2018-04-30
EP3340966A1 (fr) 2018-07-04
US9901623B2 (en) 2018-02-27
HUE060626T2 (hu) 2023-03-28
ZA201800511B (en) 2019-07-31
ES2928664T3 (es) 2022-11-21
CO2018002026A2 (es) 2018-05-21
IL256939B (en) 2019-10-31
CA2994427A1 (fr) 2017-03-02
US20210169988A1 (en) 2021-06-10
EP3340966B1 (fr) 2022-10-12
US20180140676A1 (en) 2018-05-24
HRP20221367T1 (hr) 2023-01-06
US20170056478A1 (en) 2017-03-02
EP4169505A1 (fr) 2023-04-26
PH12018500422B1 (en) 2018-08-29
IL256939A (en) 2018-03-29
MX2018002482A (es) 2018-06-15
CA2994427C (fr) 2019-07-09
SV2018005643A (es) 2018-10-09
AU2016310475A1 (en) 2018-02-15
MD3340966T2 (ro) 2023-04-30
JP6359780B2 (ja) 2018-07-18
LT3340966T (lt) 2022-11-25
RS63731B1 (sr) 2022-12-30
AR105712A1 (es) 2017-11-01
CN107920992A (zh) 2018-04-17
NZ739338A (en) 2019-06-28
TN2018000056A1 (en) 2019-07-08
CR20180118A (es) 2018-03-20

Similar Documents

Publication Publication Date Title
MA42701B1 (fr) Compositions d'insuline à action rapide
MA41188B1 (fr) Compositions d'insuline à action rapide
MA39441A1 (fr) Composition d'insuline a action rapide
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
PH12018501502A1 (en) Egf(a) analogues with fatty acid substituents
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
AU2019363725B2 (en) Stable semaglutide compositions and uses thereof
MA38646B1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
MY190102A (en) Tolerogenic dna vaccine
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
PH12020551618A1 (en) Erenumab compositions and uses thereof
MA39272A (fr) Formulations à libération prolongée de gabapentine
BR112022023738A2 (pt) Formulação líquida
MA55298A (fr) Compositions pharmaceutiques contenant des anticorps anti-lingo-1
TH1801001060A (th) องค์ประกอบอินซูลินชนิดออกฤทธิ์รวดเร็ว
TH170460A (th) "องค์ประกอบเภสัชภัณฑ์สำหรับการให้ทางปากซึ่งประกอบรวมด้วยแทกเซน"
TH168567B (th) องค์ประกอบอินซูลินออกฤทธิ์รวดเร็ว
TH168567A (th) องค์ประกอบอินซูลินออกฤทธิ์รวดเร็ว
CR20190522A (es) Composiciones de insulina de rápida acción
TN2014000127A1 (fr) Composition pharmaceutique effervescente a desagregation rapide a base de prednisolone metasulfobenzoate et son procede de fabrication
MA34795B1 (fr) Composition pharmaceutique solide pour administration buccale d'agomelatine
IN2013MU02584A (fr)